論文 - 下方 智也
-
5-FU, Irinotecan, Nab-Paclitaxel in Gastrointestinal Cancers-Letter
Maeda Osamu, Shimokata Tomoya, Ando Yuichi
CLINICAL CANCER RESEARCH 26 巻 ( 14 ) 頁： 3889 - 3889 2020年7月
-
Clinical value of serum bone resorption markers for predicting clinical outcomes after use of bone modifying agents in metastatic bone tumors: A prospective cohort study
Urakawa Hiroshi, Ando Yuichi, Hase Tetsunari, Kikumori Toyone, Arai Eisuke, Maeda Osamu, Mitsuma Ayako, Sugishita Mihoko, Shimokata Tomoya, Ikuta Kunihiro, Ishiguro Naoki, Nishida Yoshihiro
INTERNATIONAL JOURNAL OF CANCER 146 巻 ( 12 ) 頁： 3504 - 3515 2020年6月
-
Detection of bacteria in blood circulation in patients receiving cancer chemotherapy
Ota Akiko, Morita Sachi, Matsuoka Ayumu, Shimokata Tomoya, Maeda Osamu, Mitsuma Ayako, Yagi Tetsuya, Asahara Takashi, Ando Yuichi
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY 25 巻 ( 1 ) 頁： 210 - 215 2020年1月
-
Correlation Between the Metabolic Conversion of a Capecitabine Metabolite, 5 '-Deoxy-5-fluorocytidine, and Creatinine Clearance
Inaishi Takahiro, Fujita Ken-Ichi, Matsumoto Natsumi, Shimokata Tomoya, Maeda Osamu, Kikumori Toyone, Hattori Norifumi, Nakayama Goro, Ando Yuichi
IN VIVO 34 巻 ( 6 ) 頁： 3539 - 3544 2020年
-
Phase 1 study of olaratumab plus doxorubicin in Japanese patients with advanced soft-tissue sarcoma
Yonemori Kan, Kodaira Makoto, Satoh Taroh, Kudo Toshihiro, Takahashi Shunji, Nakano Kenji, Ando Yuichi, Shimokata Tomoya, Mori Joji, Inoue Koichi, Oakley Gerard J., Sakaguchi Sachi, Tamura Kenji
CANCER SCIENCE 109 巻 ( 12 ) 頁： 3962 - 3970 2018年12月
-
Reporting harms more transparently in trials of cancer drugs
Gyawali Bishal, Shimokata Tomoya, Honda Kazunori, Ando Yuichi
BMJ-BRITISH MEDICAL JOURNAL 363 巻 頁： k4383 2018年11月
-
Outpatient chemotherapy for patients with unresectable or metastatic bone sarcomas
Urakawa Hiroshi, Nishida Yoshihiro, Mitsuma Ayako, Maeda Osamu, Sugishita Mihoko, Shimokata Tomoya, Mizutani Takeshi, Arai Eisuke, Ikuta Kunihiro, Hamada Shunsuke, Ota Takehiro, Ishiguro Naoki, Ando Yuichi
ANNALS OF ONCOLOGY 29 巻 頁： . 2018年10月
-
Feasibility of dose-dense epirubicin and cyclophosphamide with subcutaneous pegfilgrastim 3.6 mg support: a single-center prospective study in Japan
Morita Sachi, Kikumori Toyone, Tsunoda Nobuyuki, Inaishi Takahiro, Adachi Yayoi, Ota Akiko, Shibata Masahiro, Matsuoka Ayumu, Nakanishi Kenichi, Takeuchi Dai, Mizutani Takefumi, Shimokata Tomoya, Hayashi Hironori, Maeda Osamu, Ando Yuichi
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY 23 巻 ( 1 ) 頁： 195 - 200 2018年2月
-
Real-world experience with FOLFIRINOX and gemcitabine plus nab-paclitaxel in the treatment of pancreatic cancer in Japan
Maeda O., Yokoyama Y., Yamaguchi J., Ota A., Matsuoka A., Morita S., Inoue M., Mizutani T., Shimokata T., Urakawa H., Mitsuma A., Nagino M., Ando Y.
ANNALS OF ONCOLOGY 28 巻 頁： 69-69 2017年11月
-
Gemcitabine plus cisplatin and S-1 for biliary tract cancer: a single institute analysis
Maeda Osamu, Shimokata Tomoya, Mizutani Takefumi, Inoue Megumi, Matsuoka Ayumu, Ota Akiko, Mizuno Takashi, Ebata Tomoki, Nagino Masato, Ando Yuichi
ANNALS OF ONCOLOGY 28 巻 頁： 50-50 2017年10月
-
Correlation and differences in Effect sizes between Progression Free Survival (PFS) and Overall Survival (OS) among PD-1 inhibitors
Gyawali B., Shimokata T., Ando Y.
ANNALS OF ONCOLOGY 28 巻 頁： . 2017年9月
-
Risk of serious adverse events and fatal adverse events with sorafenib in patients with solid cancer: a meta-analysis of phase 3 randomized controlled trials. 査読有り
Bishal Gyawali, Tomoya Shimokata, Masahiko Ando, Kazunori Honda, Yuichi Ando
Annals of Oncology 28 巻 ( 2 ) 頁： 246-253 2016年12月